3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one | 388106-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one
• 英文别名: 3-amino-2-(4-fluorophenyl)quinazolin-4-one
• CAS: 388106-35-2
• 化学式: C₁₄H₁₀FN₃O
• 分子量: 255.251
• InChiKey: LYISEFIMIOLRPY-UHFFFAOYSA-N

物化性质

• 沸点：
  429.2±47.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)
• 溶解度：
  32.9 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one 、 对溴溴苄 在 sodium hydride 作用下， 以 四氢呋喃 、 oil 为溶剂， 反应 12.08h， 生成 3-(4-bromobenzylamino)-2-(4-fluorophenyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  QUINAZOLINONE MODULATORS OF TGR5

  摘要：

  本发明涉及喹唑酮类化合物，可用作TGR5调节剂，并用于治疗或预防代谢性、心血管和炎症性疾病的方法。

  公开号：

  US20090035306A1
• 作为产物：
  描述：

  2-(4-氟苯基)-4H-3,1-苯并噁嗪-4-酮 在 肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.33h， 以98%的产率得到3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  QUINAZOLINONE MODULATORS OF TGR5

  摘要：

  本发明涉及喹唑酮类化合物，可用作TGR5调节剂，并用于治疗或预防代谢性、心血管和炎症性疾病的方法。

  公开号：

  US20090035306A1

文献信息

• Synthesis of 3-Aminoquinazolinones via a SnCl₂-Mediated ANRORC-like Reductive Rearrangement of 1,3,4-Oxadiazoles
  作者：Mohamed Elagawany、Lingaiah Maram、Bahaa Elgendy

  DOI：10.1021/acs.joc.3c01973

  日期：2023.12.15

  Herein, we developed a new SnCl2-mediated ANRORC (addition of nucleophile, ring-opening, and ring-closure)-like rearrangement for the synthesis of 3-amino-2-substituted-quinazolin-4(3H)-one from 2-(2-nitrophenyl)-5-substituted-1,3,4-oxadiazole. The new method is solvent-dependent and features the use of a green solvent system (i.e., ethanol/water), high yields, and simple workup. The reduced product

  在此，我们开发了一种新的SnCl 2介导的ANRORC（亲核试剂加成、开环和闭环）类重排，用于合成3-氨基-2-取代-喹唑啉-4(3 H )-one 2-(2-硝基苯基)-5-取代-1,3,4-恶二唑。新方法依赖于溶剂，具有使用绿色溶剂系统（即乙醇/水）、高产率和简单后处理的特点。将溶剂改为乙腈即可独家合成还原产物。
• Quinazolinone-Schiff's Base hybrids as Phosphodiesterase 4B inhibitors with dual activity against COPD and Lung Cancer
  作者：Mostafa Mansour、Mohammed El-Saadi、Noha Amin、Joshua Canzoneri、Adam Keeton、Gary Piazza、hamdy abdelrahman

  DOI：10.21608/ejchem.2020.28992.2624

  日期：2020.6.6
• WO2008/67219
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] QUINAZOLINONE MODULATORS OF TGR5<br/>[FR] MODULATEURS QUINAZOLINONES DE TGR5
  申请人：KALYPSYS INC

  公开号：WO2008067219A2

  公开（公告）日：2008-06-05

  [EN] The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.
  [FR] Cette invention concerne des composés quinazolinones utilisés en tant que modulateurs de TGR5 ainsi que des méthodes permettant de traiter ou de prévenir des maladies métaboliques, cardiovasculaires et inflammatoires.
• Synthesis of Some Noval Qunazolinone Derivatives for their Anticonvulsant Activity
  作者：Phool Singh Yaduwanshi、Sheelu Singh、Prinsi Sahapuriya、Priyanka Dubey、Jyoti Thakur、Savita Yadav

  DOI：10.13005/ojc/400207

  日期：2024.4.30

  The quinoline family comprises an appealing group of heterocyclic compounds, with quinazolinones and their synthetic analogs being of particular interest. To synthesize 3- amino 2-phenyl quinazolinones, anthranilic acid and its substituted derivatives were employed as initial materials. The MES method was utilized to evaluate the anticonvulsant activity of the developed substances on albino mice, with phenytoin serving as a benchmark anticonvulsant medication.The synthesized compounds demonstrated noteworthy anticonvulsant activity, comparable to that of established prescription medications. Among these compounds, Compound A-1 exhibited the highest level of activity. This indicates the potential of these synthetic analogs as effective anticonvulsants, with Compound A-1 standing out as particularly promising in this regard.Preliminary results indicate that certain quinazolinone derivatives exhibited promising anticonvulsant effects in the MES test. Further investigation into the mechanism of action and safety profile of these compounds is underway. The structure-activity relationships deduced from this study may guide the design of future anticonvulsant agents based on the quinazolinone scaffold.This research contributes to the ongoing efforts to discover new therapeutic options for epilepsy and provides valuable insights into the potential of quinazolinone derivatives as anticonvulsant agents. The findings underscore the importance of exploring diverse chemical structures in the quest for improved treatments for neurological disorders.